Last $33.48 USD
Change Today +0.72 / 2.20%
Volume 26.3K
GHDX On Other Exchanges
As of 11:25 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

genomic health inc (GHDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/22/13 - $37.24
52 Week Low
05/7/14 - $23.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENOMIC HEALTH INC (GHDX)

genomic health inc (GHDX) Related Businessweek News

View More BusinessWeek News

genomic health inc (GHDX) Details

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, facilitating physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as is used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.

684 Employees
Last Reported Date: 03/11/14
Founded in 2000

genomic health inc (GHDX) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $600.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $469.2K
Executive Vice President of Research & Develo...
Total Annual Compensation: $459.2K
Total Annual Compensation: $353.8K
Compensation as of Fiscal Year 2013.

genomic health inc (GHDX) Key Developments

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX(R) as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients

Genomic Health Inc. announced strongly positive results from an additional independent clinical validation study of the Oncotype DX(R) prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence). In meeting these two endpoints, the Oncotype DX prostate cancer test provides both clinically actionable and long-term outcomes information for men with newly diagnosed low- and intermediate-risk prostate cancer. Furthermore, the study demonstrated that Oncotype DX is similarly predictive of outcomes in both Caucasian and African-American men. The key results of this large prospectively-designed study in 402 patients are based on the CPDR multi-center national database: the biopsy-based Oncotype DX GPS was a robust and independent measure of multiple clinically relevant endpoints, including adverse surgical pathology (p<0.001) and long-term risk of biochemical recurrence after surgery (p<0.001); the Oncotype DX GPS was very similarly predictive of outcomes in Caucasian and African-American men regardless of their race. African-American men represented 20% of this study's patient population; and the established multiple prostate cancer-specific pathways contributed to the robust predictive value of the Oncotype DX GPS. The Oncotype DX GPS was also significantly predictive of metastatic prostate cancer recurrence (p = 0.032), a notable finding given the likelihood of metastases in patients with low- and intermediate-risk prostate cancer is so small.

Genomic Health Inc. Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics

Genomic Health Inc. announced that PharmacoEconomics 70ublished positive results from a health economic analysis suggesting that use of the Oncotype DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment. The analysis of 141 patients from 17 sites in the Mayo Clinic Cancer Research Consortium demonstrated the value of using the Oncotype DX test to identify stage II colon cancer patients with low risk of recurrence, who may consider forgoing a chemotherapy regimen. After physicians received the Recurrence Score results, their recommendations for adjuvant chemotherapy in patients with low risk of recurrence decreased by 22%, which resulted in direct medical care cost savings of approximately $1,000 per patient. This is the first health economic study of the Oncotype DX colon cancer test conducted in clinical practice. A previous, separate modeling study showing that the use of the Oncotype DX test in stage II colon cancer patients may lead to health care cost savings while improving clinical outcomes was published in 2012 by Value of Health.

Genomic Health Inc. Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study

Genomic Health Inc. announced that results from nine studies of Oncotype DX in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology 2014 Congress in Madrid, September 26 to 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville, Md. This new study demonstrates the test's ability to predict a rise in prostate-specific antigen (PSA) following surgery and reconfirms Oncotype DX as a predictor of adverse pathology from the biopsy, as previously demonstrated in a published validation study performed by the University of California, San Francisco. Collectively, data being presented at the conference showcase the company’s successful approach to understanding tumor biology across different cancer types and highlight the following: Additional clinical validation of the Oncotype DX prostate cancer test, demonstrating its ability to predict both actionable and long term clinical endpoints related to disease aggressiveness. Further evidence of the practice-changing impact of the Oncotype DX test in breast cancer. The consistent importance of assessing multiple, disease relevant, biological pathways to predict tumor behavior.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GHDX:US $33.48 USD +0.72

GHDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $23.03 USD +0.53
LipoScience Inc $5.21 USD 0.00
NanoString Technologies Inc $10.42 USD +0.17
NeoGenomics Inc $4.69 USD -0.05
Veracyte Inc $7.75 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation GHDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOMIC HEALTH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at